Abcam, ab303675, Anti-CCR9 antibody [9B1] - BSA and Azide Free

Size: 100µg / 1mg
Rat Recombinant Monoclonal CCR9 antibody. Carrier free. Suitable for Flow Cyt and reacts with Mouse samples.
Key facts
Host species:Rat,
Clonality:Monoclonal,
Clone number:9B1,
Isotype:IgG2a,
Carrier free:Yes,
Reacts with:Mouse,
Applications:Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab303674
is the carrier-free version of ab303675.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Want a custom formulation?
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CCR9 also known as CD199 is a chemokine receptor known for its role in guiding cell traffic. It is a G-protein-coupled receptor with a mass of approximately 43 kDa. CCR9 is mainly expressed on the surface of thymocytes T lymphocytes and some subsets of dendritic cells. Its presence is especially noted in the small intestine correlated with its role in the migration and function of immune cells in the gut. This receptor is important for the homing of these cells to the intestinal mucosa engaging specifically with its ligand CCL25.
Biological function summary
CCR9 plays a significant role in the immune system particularly in the gut. It is part of chemokine receptor-ligand complexes that are integral to leukocyte trafficking. By interacting with CCL25 CCR9 facilitates the directed movement of immune cells across intestinal tissue impacting the immune surveillance and response within this environment. The receptor's expression pattern also suggests involvement in thymocyte development supporting the immune system's ability to generate a diverse repertoire of T cells.
Pathways
CCR9 is an important component of the chemokine signaling pathway. It is intricately connected to G-protein signaling events triggering downstream effects that drive cell migration and adhesion. This pathway is important for the function and maintenance of mucosal immunity linking CCR9 with CCR7 and its role in guiding T cell migration to specific tissue sites. These pathways collectively support immune functionality and homeostasis underlining CCR9's significance in tissue-specific immunity.
CCR9 has associations with inflammatory disorders like Crohn's disease and ulcerative colitis. Inflammatory bowel disease (IBD) is marked by aberrant immune cell movement and function areas where CCR9 is particularly influential. The receptor's interaction with CCL25 is pivotal in these pathological conditions often being a therapeutic target to modulate immune cell trafficking in disease management. Additionally the altered expression of CCR9 may contribute to the progression of specific T-cell leukemias further emphasizing its clinical relevance.